BioTrove and Sitris Expand HTS Relationship
News Nov 10, 2005
BioTrove has announced the expansion of its relationship with Sirtris Pharmaceuticals. As part of the ongoing relationship, BioTrove will use its proprietary RapidFire™ Lead Discovery service for assay development and high throughput screening on an undisclosed number of Sirtris targets.
RapidFire™ Lead Discovery uses high throughput mass spectrometry to perform label-free assays using native biological substrates enabling the screening of intractable targets.
“The expansion of our relationship with Sirtris provides further validation of the value of RapidFire™ Lead Discovery,” said Alan Carter, vice president of business development and field operations.
“Our expanding customer base continues to find new leads and information on valuable targets when compared to classical HTS methods.”
XenoGesis and BioAscent Forge Alliance to Offer Enhanced Integrated Drug Discovery ServicesNews
XenoGesis and BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal chemistry, biology and DMPK.READ MORE
BioAscent Establishes Integrated Drug Discovery Services OfferingNews
Dr Phil Jones to join as new CSO to lead company’s extended capabilities in medicinal chemistry and in vitro biosciences.READ MORE
Lab Innovations returns to the NEC, Bimingham , UKNews
Save the date for the UK’s only lab-dedicated exhibition showcase!READ MORE